BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary FibrosisTalmadge E. King, Fernando Martínez, Dominique Valeyre et al.|American Journal of Respiratory and Critical Care Medicine|2011Cited by 713
Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLCByoung Chul Cho, Patricia Lorenzini, Shun Lu et al.|New England Journal of Medicine|2024Cited by 369
MA07.07 Validation Analysis of MET IHC as a Biomarker for Amivantamab-Lazertinib Response in Post-Osimertinib EGFR-Mutated NSCLCBenjamin Besse, E. Felip, P. Tomasini et al.|Journal of Thoracic Oncology|2025Cited by 1